Bisphosphonate Therapy for Osteoporosis

  • Nelson B. Watts

Abstract

Bisphosphonate treatment of osteoporosis began with off-label use of etidronate in the 1980s. Alendronate (1995) and rise-dronate (1999). are approved by the US Food and Drug Administration (FDA) for prevention and treatment of post-menopausal osteoporosis and for patients with osteoporosis due to glucocoprticoid treatment. These compounds increase bone mineral density and reduce the risk of fractures of the vertebrae, hips, and other nonvertebral sites. The body of evidence for both safety and efficacy of bisphosphonate treatment of osteoporosis is stronger than for any other agent. Bisphosphonates are safe and well tolerated and represent the agents of choice for most patients with osteoporosis.

Keywords

Bone Mineral Density Vertebral Fracture Zoledronic Acid Postmenopausal Osteoporosis Bone Turnover Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Watts NB: Bisphosphonate treatment for osteoporosis. In The Osteoporotic Syndrome. Edited by Avioli LV. San Diego: Academic Press, 2000:121–132.CrossRefGoogle Scholar
  2. 2.
    Rogers MJ, Gordon S, Benford HL, et al.: Cellular and molecular mechanisms of action of bisphosphonates [review]. Cancer 2000,88(12 suppl):2961–2978.PubMedCrossRefGoogle Scholar
  3. 3.
    Tucci JR,Tonino RR Emkey RD, et al.: Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996, 101:488–501.CrossRefGoogle Scholar
  4. 4.
    Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis—a randomized controlled trial. JAMA 1999, 282:1344–1352.PubMedCrossRefGoogle Scholar
  5. 5.
    Hosking D, Chilvers CED, Christiansen C, et al: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998,338:485–492.PubMedCrossRefGoogle Scholar
  6. 6.
    Orwoll E, Ettinger M, Weiss S, et al: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610.PubMedCrossRefGoogle Scholar
  7. 7.
    Reid DM, Hughes R, Laan RF, et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000, 15:1006–1013.PubMedCrossRefGoogle Scholar
  8. 8.
    Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535–1541.PubMedCrossRefGoogle Scholar
  9. 9.
    Wallach S, Cohen S, Reid DM, et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. CalcifTissue Int 2000,67:277–285.CrossRefGoogle Scholar
  10. 10.
    Tonino RP, Meunier PJ, Emkey R, et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000,85:3109–3115.PubMedCrossRefGoogle Scholar
  11. 11.
    Schnitzer TJ, Bone HG, Crepaldi G, et al.: Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily for treatment of postmenopausal osteoporosis. Ag/ng Clin Exp Res 2000, 12:1–12.Google Scholar
  12. 12.
    Brown JP, Kendler DL, McClung MR, et at.:The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. CalcifTissue Int 2002, 71:103–111.CrossRefGoogle Scholar
  13. 13.
    Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002,346:653–661.PubMedCrossRefGoogle Scholar
  14. 14.
    Bone HG, Greenspan SL, McKeever C, et al.: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000,85:720–726.PubMedCrossRefGoogle Scholar
  15. 15.
    Compston JE, Watts NB: Combination therapy for postmenopausal osteoporosis. Clin Endocrinol 2002, 56:565–569.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Nelson B. Watts

There are no affiliations available

Personalised recommendations